TY - JOUR
T1 - Comorbid extra-intestinal central sensitization conditions worsen irritable bowel syndrome in primary care patients
AU - Wang, Xiao Jing
AU - Ebbert, Jon O.
AU - Loftus, Connor G.
AU - Rosedahl, Jordan K.
AU - Philpot, Lindsey M.
N1 - Funding Information:
This study was funded by the Mayo Clinic Alix College of Medicine and Science.
Publisher Copyright:
© 2023 John Wiley & Sons Ltd.
PY - 2023/4
Y1 - 2023/4
N2 - Background: Irritable bowel syndrome (IBS) is characterized as a central sensitization syndrome (CSS), a group of conditions including fibromyalgia, chronic fatigue, and restless leg syndrome (RLS) among others with frequent comorbidities of anxiety, depression, and chemical sensitivity. The prevalence of comorbid conditions and their impact on IBS symptom severity and quality of life in rural community populations has not been described. Methods: We administered a cross-sectional survey to patients with a documented CSS diagnosis in rural primary care practices to evaluate the relationship between CSS diagnoses, quality of life, symptom severity, and interactions with healthcare providers utilizing validated questionnaires. Subgroup analysis was performed on the IBS cohort. Mayo Clinic IRB approved the study. Key Results: Seven hundred seventy-five individuals out of 5000 completed the survey (15.5% response rate) with 264 (34%) reporting IBS. Only 3% (n = 8) of IBS patients reported IBS alone without comorbid CSS condition. Most respondents reported overlapping migraine (196, 74%), depression (183, 69%), anxiety (171, 64%), and fibromyalgia (139, 52%). IBS patients with more than two comorbid CS condition showed significantly higher symptom severity with linear increase. Quality of life was lower in IBS with comorbid conditions, particularly in patients with IBS and RLS (mean EQ5-D 0.36 vs. 0.8 in IBS only, p < 0.01). Quality of life declined as number of comorbid conditions increased. Conclusions & Inferences: Patients with IBS often have multiple CS disorders which increases symptom severity and lowers quality of life. Understanding the impact of multiple CSS diagnoses and treating these as a global condition may improve patient experience.
AB - Background: Irritable bowel syndrome (IBS) is characterized as a central sensitization syndrome (CSS), a group of conditions including fibromyalgia, chronic fatigue, and restless leg syndrome (RLS) among others with frequent comorbidities of anxiety, depression, and chemical sensitivity. The prevalence of comorbid conditions and their impact on IBS symptom severity and quality of life in rural community populations has not been described. Methods: We administered a cross-sectional survey to patients with a documented CSS diagnosis in rural primary care practices to evaluate the relationship between CSS diagnoses, quality of life, symptom severity, and interactions with healthcare providers utilizing validated questionnaires. Subgroup analysis was performed on the IBS cohort. Mayo Clinic IRB approved the study. Key Results: Seven hundred seventy-five individuals out of 5000 completed the survey (15.5% response rate) with 264 (34%) reporting IBS. Only 3% (n = 8) of IBS patients reported IBS alone without comorbid CSS condition. Most respondents reported overlapping migraine (196, 74%), depression (183, 69%), anxiety (171, 64%), and fibromyalgia (139, 52%). IBS patients with more than two comorbid CS condition showed significantly higher symptom severity with linear increase. Quality of life was lower in IBS with comorbid conditions, particularly in patients with IBS and RLS (mean EQ5-D 0.36 vs. 0.8 in IBS only, p < 0.01). Quality of life declined as number of comorbid conditions increased. Conclusions & Inferences: Patients with IBS often have multiple CS disorders which increases symptom severity and lowers quality of life. Understanding the impact of multiple CSS diagnoses and treating these as a global condition may improve patient experience.
KW - central sensitization
KW - central sensitization syndrome
KW - fibromyalgia
KW - irritable bowel syndrome
UR - http://www.scopus.com/inward/record.url?scp=85148518121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148518121&partnerID=8YFLogxK
U2 - 10.1111/nmo.14546
DO - 10.1111/nmo.14546
M3 - Article
C2 - 36807964
AN - SCOPUS:85148518121
SN - 1350-1925
VL - 35
JO - Neurogastroenterology and Motility
JF - Neurogastroenterology and Motility
IS - 4
M1 - e14546
ER -